[Peritoneal carcinomatosis from ovarian cancer: role of 18F-FDG-PET/CT and CA125]

Recenti Prog Med. 2012 Nov;103(11):510-4. doi: 10.1701/1166.12898.
[Article in Italian]

Abstract

The purpose of this study was to evaluate the contribution of 18F-FDG-PET/CT in highlighting the peritoneal involvement in patients with ovarian cancer, also in relation to the biomarker CA125. We retrospectively analyzed 64 female patients with histological diagnosis of ovarian cancer who underwent 18F-FDG-PET/CT and CA125 measurement. Sensitivity and specificity of 18F-FDG-PET/CT were both 90.63% (95% CI: 80-100%). Sensitivity and specificity of CA125 were 93.33% (95% CI: 80-100%) and 33.33% (95% CI: 25-64%), respectively. In patients with peritoneal carcinomatosis from ovarian cancer, it is recommended to perform 18F-FDG-PET/CT, in particular when elevated CA125 levels are detected.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • CA-125 Antigen / blood*
  • Carcinoma / blood
  • Carcinoma / diagnostic imaging*
  • Carcinoma / secondary*
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Middle Aged
  • Multimodal Imaging*
  • Ovarian Neoplasms / blood
  • Ovarian Neoplasms / pathology*
  • Peritoneal Neoplasms / blood
  • Peritoneal Neoplasms / diagnostic imaging*
  • Peritoneal Neoplasms / secondary*
  • Positron-Emission Tomography*
  • Radiopharmaceuticals*
  • Retrospective Studies
  • Tomography, X-Ray Computed*

Substances

  • CA-125 Antigen
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18